Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer
Megadott ok: End of recruiting period
Key facts
- Where
- Lille, FranciaországSee the site
Where in Franciaország
- Centre Oscar LambretLille, FranciaországNo longer taking part
Trial details
- Who runs it
- Centre Oscar Lambret
- Trial code
- NCT03922776
- Record updated
- 2026. március 18.
- Original description
This is a monocenter, interventional, non-randomized study among women patients with an ovarian or tubal cancer who will receive a surgery or adjuvant chemotherapy treatment, or a neo-adjuvant chemotherapy then surgery +/- adjuvant chemotherapy. The planned interventions are collection of biological samples at different times. The study will aim to describe the immunological profile at diagnosis in terms of phenotypic : PBMCs (peripheral blood, mononuclear cells) in peripheral blood, TILs (tumor-infiltrating lymphocytes) in ascites and in carcinomatosis.Read full original descriptionShow less
Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Advanced High-grade Serous Ovarian Cancer in Blood, Ascites, Peritoneal Biopsy
This is a monocenter, interventional, non-randomized study among women patients with an ovarian or tubal cancer who will receive a surgery or adjuvant chemotherapy treatment, or a neo-adjuvant chemotherapy then surgery +/- adjuvant chemotherapy. The planned interventions are collection of biological samples at different times. The study will aim to describe the immunological profile at diagnosis in terms of phenotypic : PBMCs (peripheral blood, mononuclear cells) in peripheral blood, TILs (tumor-infiltrating lymphocytes) in ascites and in carcinomatosis.
Inclusion: 18 years old or more; Presenting a carcinomatosis with suspicion of ovarian cancer or tubal cancer, under a diagnostic laparoscopy; Stage IIIC or initial pleural IV; Planned treatment with surgery and adjuvant chemotherapy, or neo-adjuvant chemotherapy followed by surgery +/- adjuvant chemotherapy; Having been informed and signed the informed consent of this study; Affiliated with a social security scheme.
Exclusion: Contraindication to surgery and / or chemotherapy; Stage IV with visceral metastases (pulmonary, hepatic ...); Pregnant or lactating woman; Patient under guardianship or curatorship.